RIGL Rigel Pharmaceuticals, Inc.

-0.06  -2%
Previous Close 2.48
Open 2.54
Price To book 3.61
Market Cap 296.29M
Shares 122,434,000
Volume 386,836
Short Ratio 2.82
Av. Daily Volume 1,126,830

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
IgA nephropathy
Phase 2 trial did not meet endpoints
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. NDA submission announced April 17, 2017.
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data from first of two stages due in 2017.
Autoimmune hemolytic anemia (AIHA)

Latest News

  1. ETFs with exposure to Rigel Pharmaceuticals, Inc. : May 16, 2017
  2. 3 Biotech Stocks I'd Buy Right Now
  3. Edited Transcript of RIGL earnings conference call or presentation 2-May-17 9:00pm GMT
  4. Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
  5. Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : May 3, 2017
  6. Rigel reports 1Q loss
  7. Rigel Announces First Quarter 2017 Financial Results and Provides Company Update
  8. Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call
  9. Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States
  10. Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results
  11. Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug
  12. Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
  13. 5 Top Breakout Stocks to Boost Your Portfolio
  14. Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher?
  15. After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?
  16. Will Rigel Pharmaceuticals (RIGL) Continue to Surge Higher?
  17. 3 Beaten-Up Biotech Stocks: Are They Bargains?
  18. 3 Stocks That Are Ridiculously Cheap Right Now
  19. 5 Cheap Breakout Stocks for Superb Returns